Scholars Central

Research articlePublished 2018

Assessment of Posaconazole Salvage Therapy in Chronic Pulmonary Aspergillosis by Using Predefined Response Criteria

Authors: Goncer IR, Harris C, Kosmidis C, Muldoon EG, Newton PJ, Denning DW

Journal of Antimicrobial Agents

Volume 4 · Issue 1 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Objective: Chronic pulmonary aspergillosis (CPA) is a progressive infection that destroys lung tissue in immune competent patients. First-line therapies for CPA (itraconazole and/or voriconazole) are often curtailed due to toxicity or the development of drug resistance. Posaconazole is a potential alternative for these patients, but it is a high-cost medication. Methods: Use of posaconazole was funded by the NHS Highly Specialised National Commissioners on an individual basis for patients who failed or did not tolerate first line therapy; those who met predefined criteria for improvement at 4 and 6 months (weight gain and/or improvement in St George’s Respiratory Questionnaire) continued posaconazole long-term. We recorded response, failure, discontinuation rates and adverse events. Results: Seventy-eight patients received posaconazole as salvage therapy. Thirty-four (44%) achieved targets for continuation of therapy. Fourteen (18%) failed therapy; 5 (36%) patients did not achieve clinical targets at 4 or 6 months of assessment and 9 (64%) developed clinical and/or radiological failure. Twenty-eight (36%) discontinued their trial early; 8 (29%) died and 20 (71%) had significant side effects. One patient was non-compliant and another was lost to follow-up. Conclusions: Establishing criteria for therapeutic success offered a clear, safe and sustainable method of identifying patients who benefit from additional therapy and minimised continuation of ineffective therapy in those who did not.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Antimicrobial Agents.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Antimicrobial Agents
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Goncer IR”
  • BylineArticles whose byline prints “Harris C”
  • BylineArticles whose byline prints “Kosmidis C”
  • BylineArticles whose byline prints “Muldoon EG”
  • BylineArticles whose byline prints “Newton PJ”
  • BylineArticles whose byline prints “Denning DW”